当前位置: 首页 >> 检索结果
1389. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
作者: Simron Singh.;Daniel Halperin.;Sten Myrehaug.;Ken Herrmann.;Marianne Pavel.;Pamela L Kunz.;Beth Chasen.;Salvatore Tafuto.;Secondo Lastoria.;Jaume Capdevila.;Amparo García-Burillo.;Do-Youn Oh.;Changhoon Yoo.;Thorvardur R Halfdanarson.;Stephen Falk.;Ilya Folitar.;Yufen Zhang.;Paola Aimone.;Wouter W de Herder.;Diego Ferone.; .
来源: Lancet. 2024年403卷10446期2807-2817页
There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) treatment.
1392. Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial.
作者: Christopher Patrick Bretherton.;Juul Achten.;Vidoushee Jogarah.;Stavros Petrou.;Nicholas Peckham.;Felix Achana.;Duncan Appelbe.;Rebecca Kearney.;Harry Claireux.;Philip Bell.;Xavier L Griffin.; .
来源: Lancet. 2024年403卷10446期2787-2797页
After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy.
1393. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Hans Gelderblom.;Vivek Bhadri.;Silvia Stacchiotti.;Sebastian Bauer.;Andrew J Wagner.;Michiel van de Sande.;Nicholas M Bernthal.;Antonio López Pousa.;Albiruni Abdul Razak.;Antoine Italiano.;Mahbubl Ahmed.;Axel Le Cesne.;Gabriel Tinoco.;Kjetil Boye.;Javier Martín-Broto.;Emanuela Palmerini.;Salvatore Tafuto.;Sarah Pratap.;Benjamin C Powers.;Peter Reichardt.;Antonio Casado Herráez.;Piotr Rutkowski.;Christopher Tait.;Fiona Zarins.;Brooke Harrow.;Maitreyi G Sharma.;Rodrigo Ruiz-Soto.;Matthew L Sherman.;Jean-Yves Blay.;William D Tap.; .
来源: Lancet. 2024年403卷10445期2709-2719页
Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery.
1398. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
作者: Xu Liu.;Yuan Zhang.;Kun-Yu Yang.;Ning Zhang.;Feng Jin.;Guo-Rong Zou.;Xiao-Dong Zhu.;Fang-Yun Xie.;Xiao-Yu Liang.;Wen-Fei Li.;Zhen-Yu He.;Nian-Yong Chen.;Wei-Han Hu.;Hai-Jun Wu.;Mei Shi.;Guan-Qun Zhou.;Yan-Ping Mao.;Rui Guo.;Rui Sun.;Jing Huang.;Shao-Qiang Liang.;Wei-Li Wu.;Zhen Su.;Ling Li.;Ping Ai.;Yu-Xiang He.;Jian Zang.;Lei Chen.;Li Lin.;Shao Hui Huang.;Cheng Xu.;Jia-Wei Lv.;Ying-Qing Li.;Shu-Bin Hong.;Yu-Sheng Jie.;Hao Li.;Sai-Wei Huang.;Ye-Lin Liang.;Ya-Qin Wang.;Ying-Lin Peng.;Jin-Han Zhu.;Sheng-Bing Zang.;Song-Ran Liu.;Qing-Guang Lin.;Hao-Jiang Li.;Li Tian.;Li-Zhi Liu.;Hong-Yun Zhao.;Ai-Hua Lin.;Ji-Bin Li.;Na Liu.;Ling-Long Tang.;Yu-Pei Chen.;Ying Sun.;Jun Ma.
来源: Lancet. 2024年403卷10445期2720-2731页
Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population.
|